Clinical Trial Detail

NCT ID NCT04191135
Title Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.

triple-receptor negative breast cancer


Carboplatin + Gemcitabine + Pembrolizumab

Carboplatin + Gemcitabine + Olaparib + Pembrolizumab

Age Groups: senior adult

No variant requirements are available.